If licensed, denosumab will offer an alternative

). This prevents

contact with its receptor on the surface of osteoclast precursors and osteoclasts thereby inhibiting osteoclast differentiation, activation and survival. Increased osteoclast activity is crucial in the pathogenesis of disease resulting from excessive bone resorption such as osteoporosis and cancer-related bone metastases. Denosumab is every 6 months, subcutaneous (SC) injection in doses of 60 mg. Denosumab is licensed in the EU for the treatment of osteoporosis in postmenopausal women with increased risk of fractures and treatment of bone loss associated with hormonal ablation in men with prostate cancer with an increased risk of fractures. It was launched in the U.S. and pending

for the prevention of bone events related to the (cancer of bone injury), patients with bone metastases of solid tumors lasix 100 mg, and pre-registration in the U.S., Canada, Switzerland and other countries for bone loss associated with hormonal ablation in breast cancer. If licensed, denosumab will offer an alternative treatment regimen for this group of patients with the convenience of 6 months of dosing. This may be a specific variant of renal failure, when several other treatments are contraindicated. .